TrialOncotarget2016
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
Lorenza Rimassa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
38 papers cite it
this paperpooled ittrialcites it